Challenges and Strategies for Tackling Drug Regulation Evasion in North East Africa

The pharmaceutical industry in North East Africa faces a critical challenge in the form of substandard and falsified drugs, compromising public health and safety. Regulatory guidance plays a crucial role in ensuring the quality and authenticity of medicines, but the region grapples with issues related to circumvention. This article explores the factors contributing to the circumvention of regulatory guidance and examines potential strategies to address this pressing issue.

Factors Contributing to Circumvention

Weak Regulatory Infrastructure

• The North East African region struggles with weak regulatory infrastructure, hindering effective oversight of pharmaceutical products. Limited resources, inadequate training, and insufficient personnel contribute to regulatory gaps that unscrupulous actors exploit. As a result, substandard or falsified drugs find their way into the market, posing serious risks to public health.

Corruption and Lack of Enforcement

• Corruption within regulatory bodies and law enforcement agencies further exacerbates the problem. Some individuals exploit their positions for personal gain, accepting bribes to overlook substandard or falsified drugs entering the market. This compromises the effectiveness of regulatory measures and undermines public trust in the healthcare system.

Porosity of Borders

• The porous borders in the region facilitate the illicit movement of pharmaceuticals, making it challenging to control the entry of substandard or falsified drugs. Smugglers take advantage of weak border controls to traffic counterfeit medicines across countries, evading regulatory scrutiny.

Strategies to Address Circumvention

Enhancing Regulatory Capacity

• Strengthening regulatory capacity is paramount to combating the circumvention of regulatory guidance. Governments and international organizations should invest in training regulatory personnel, providing them with the skills and resources necessary to enforce robust oversight. This includes updating regulatory frameworks, implementing international quality standards, and ensuring adequate funding for regulatory agencies.
  

Transparency and Accountability Measures

1. Implementing transparency and accountability measures is crucial for combating corruption within regulatory bodies. Governments should establish mechanisms for reporting and investigating corrupt practices, with severe consequences for those found guilty. Additionally, fostering a culture of transparency in pharmaceutical supply chains helps track the movement of drugs, reducing the likelihood of substandard or falsified products reaching consumers.
   Reference: Transparency International. (2022). Global Corruption Report: Pharmaceuticals. Retrieved from https://www.transparency.org/whatwedo/publication/global_corruption_report_pharmaceuticals

Regional Collaboration and Information Sharing

• Given the cross-border nature of the issue, regional collaboration is essential. Countries in North East Africa should work together to share information on substandard or falsified drugs, coordinate regulatory efforts, and establish joint initiatives to combat illicit pharmaceutical trade. Regional organizations and international bodies can play a pivotal role in facilitating such collaboration.
  Reference: World Health Organization. (2021). Regional Collaboration for Medicine Regulatory Harmonization. Retrieved from https://www.who.int/medicines/areas/quality_safety/regulation_legislation/med_reg_harmonization/en/

Real-time Intelligence and Remediation

An essential component of strategies designed to discover and remove SF drugs from the supply chain must incorporate the testing of products to determine their quality and safety. The targeted introduction of chemical analysis where these medicines are located in the supply chain – hospitals, pharmacies, warehouses, manufacturer inventories and the like – provides actionable information for stakeholders to issue alerts, sequester questionable products for further testing, replace suspect shipments, purchase alternative medicines, and monitor patient status, among other interventions.

The ARTiFACTS Verify platform offers an integrated approach to identifying substandard and falsified drugs that have entered the pharmaceutical supply chain:

• Identification of suspect medicines through on-site testing at any point in the supply chain using paper analytical device technology that is cost-effective and requires minimal training.
• Confirmation of the properties of medicines failing the initial test through further testing at specialist labs, using advanced scientifically recognized techniques, including high-performance liquid chromatography, mass spectroscopy, among others.
• Organisation of all data captured for managing workflows, analysing and reporting results.
• Coverage of over half of WHO’s 600 Essential Medicines.

Enhanced data security by recording results on a purpose-built blockchain provides an immutable record of test results, including active pharmaceutical ingredients, product origin, manufacturer and other data essential for effective intervention.

Conclusion

Addressing the circumvention of regulatory guidance for substandard or falsified drugs in North East Africa requires a multifaceted approach. Strengthening regulatory capacity, implementing transparency measures, and fostering regional collaboration are essential components of a comprehensive strategy. By addressing these challenges, governments and stakeholders can safeguard public health, ensure the integrity of pharmaceutical products, and restore trust in the healthcare system.